We are studying how well Avacopan works when combined with other treatments in children aged 6 to under 18 with active ANCA-associated vasculitis. The trial will also look at safety and how children respond to the medication.
We are studying a new way to deliver radiolabeled treatments directly to the liver for patients with GEP-NET and dominant liver metastases. This trial aims to see if this method improves treatment effectiveness and safety.
We are investigating how Enzalutamide affects molecular changes in men with localized prostate cancer before and after surgery. This study may help us understand its impact on cell growth and gene activity.
We are studying new treatment options for children and adolescents with hard-to-treat tumors. The goal is to see if these treatments are safe and effective based on the specific characteristics of their tumors.
We are investigating whether different concentrations of ropivacaine can help reduce pain after volar plate surgery. This study aims to see if higher doses lead to less rebound pain and better overall pain control.
We are studying a new combination treatment for patients with operable Non-Small-Cell Lung Cancer to see if it improves response rates before surgery. We also aim to identify markers that may predict how well patients respond to this therapy.
We are studying a combination of ibrutinib and obinutuzumab for newly diagnosed patients with Chronic Lymphocytic Leukemia. The aim is to see if this treatment effectively reduces cancer cells in the bone marrow.
We are studying whether vitamin D supplements can help increase testosterone levels in men with type 2 diabetes. This trial compares the effects of vitamin D to a placebo.
We are studying whether nebulized ensifentrine can help reduce lung flare-ups in people with non-cystic fibrosis bronchiectasis. The trial also examines its impact on respiratory symptoms and overall quality of life.
We are studying the safety and effectiveness of CRN04894 in participants with hormonal imbalances. The goal is to see how it affects hormone levels and overall health.
We are exploring whether high-throughput molecular analysis can help guide treatment for patients with advanced soft-tissue sarcomas. This study will compare treatment outcomes for those receiving NGS-guided therapy versus standard care.
We are studying a new treatment combining venetoclax and azacitidine with donor lymphocyte infusion for patients with MDS or AML who have relapsed after a stem cell transplant. The goal is to assess its safety and effectiveness.
We are comparing the effects of intraperitoneal paclitaxel combined with standard therapy against standard therapy alone in patients with gastric cancer and peritoneal metastases. This study aims to see if the combination improves survival and quality of life.
We are investigating whether MYRRHINIL-INTEST® is effective and safe for people with diarrhoea-dominant and mixed-type irritable bowel syndrome. This study compares it to a placebo to see how well it works.
We are studying whether a 5-day antibiotic treatment is as effective and safe as longer treatments for hospitalized adults with Gram-negative bacteremia from urinary tract infections.
We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.
We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.
We are testing a single dose of intravenous Dalbavancin against standard antibiotics for patients with bloodstream infections. The goal is to see if Dalbavancin is as effective and to evaluate its impact on recovery and quality of life.
We are testing new drugs for patients with relapsed or refractory peripheral T-cell lymphomas to see if they are safe and improve treatment outcomes. This trial aims to find better options for those who have not responded to existing therapies.
We are offering ongoing access to avapritinib for adults who benefited from it in a prior study. This trial also aims to evaluate the long-term safety of the treatment.